ImmuPharma PLC: Encouraging Final Phase IIb Results Seen with LUPUZOR(TM) in Systemic Lupus Erythematosus ~ Greatest Benefits Seen in Patients with Moderate to Severe Systemic Lupus Erythematosus ~
LONDON, Nov 19, 2009 (BUSINESS WIRE) -- ImmuPharma PLC (LSE:IMM) the specialist discovery and development pharmaceutical company is pleased to announce today the final results from a Phase IIb trial of LUPUZOR(TM) in active patients with Systemic Lupus Erythematosus (SLE). Lupuzor(TM) administ…
Continue
Added by Angie on November 29, 2009 at 5:00pm —
No Comments